ENA Respiratory is a clinical-stage pharmaceutical company developing intranasal innate immune enhancers for the prevention of complications resulting from respiratory viral infections in at-risk populations.Headquartered in Melbourne, Australia, the company has raised US$26M (AU$38.6 million) in equity financing from Brandon Capital, The Minderoo Foundation and Uniseed. It has been awarded a US$11.3M contract from the U.S. Department of Defence and also partnered with the US COPD Foundation to support the clinical development of its lead asset in COPD. ENA Respiratory is an alumnus of BLUE KNIGHT™, a joint initiative between Johnson & Johnson Innovation and BARDA designed to accelerate novel potential solutions for future pandemics.

SVI is a leading Australian medical research institute, affiliated with St Vincent’s Hospital and the University of Melbourne. Research at SVI focus on the cause, prevention and treatment of diseases that are common and have serious effects on health, including diabetes, cancer, infectious diseases, arthritis, osteoporosis, Alzheimer's and other neurological disorders.

Axelia Oncology is a biopharmaceutical company aiming to transform the treatment of checkpoint insensitive cancers through the activation of TLR2/6 engagement of the innate immune response.

Otifex Therapeutics is developing a new treatment for the most common cause of acquired hearing loss in childhood, Otitis Media with Effusion (OME or ‘glue ear’). Otifex was spun out from The University of Melbourne in 2009 and in late 2010 the company attracted seed investment funding from the Medical Research Commercialisation Fund (MRCF) and Uniseed.See www.otifex.com for additional information.

Commercial engagement service company of the University of Melbourne, AustraliaReporting directly to the acting CEO and with 7 direct and indirect reports, responsible for the activities and performance of the Technology Commercialisation Group.Additional responsibilities:- Member of the Executive Management Team- Managing the life sciences-related Technology Commercialisation portfolio- Fund Manager for the Melbourne Technology Accelerator Fund- Non-executive director of Otifex Therapeutics Pty Ltd and BACE Therapeutics Pty Ltd- Acting CEO, Innavac Pty Ltd

Satrt-up from the Walter and Eliza Hall Institute of Medical Research (WEHI), the University of Melbourne and the Mental Health Research Institute to develop small molecule for the treatment of Alzheimer’s disease

Oncology-focused development and commercialisation company responsible for the valorisation of discoveries arising from prestigious international cancer research institutes. CRT has its own R&D laboratory with competences in drug discovery - [www.cancertechnology.com]Reporting to a Senior Business Manager with a direct report, responsible for crystallising partnerships in relation to cancer technologies funded by Cancer Research UK.

Reporting to the Research Director, responsible for leading the gene delivery program of the company and providing scientific and technical support during discussion with potential commercial partners.

Research Focus: Viral gene transfer into haematopoietic stem cells. This work led in 2002, to Britain's first successful gene therapy clinical trial for the treatment of immune deficiencies in children